Citrate anticoagulants for plateletpheresis

Area of Science:

• Hematology
• Blood Component Collection
• Apheresis Technology

Background:

• Plateletpheresis is a critical procedure for collecting platelet concentrate.
• Anticoagulant solutions are essential for preventing blood clotting during apheresis.
• Different anticoagulant formulas may impact collection efficiency and donor safety.

Purpose of the Study:

• To compare the effectiveness of three anticoagulant solutions: ACD formula A, ACD formula B, and 2% citrate in saline.
• To evaluate the impact of these anticoagulants on platelet and white blood cell yields.
• To assess the incidence of citrate-related reactions in donors during plateletpheresis.

Main Methods:

• A total of 112 plateletpheresis procedures were performed using a Haemonetics blood processor.
• The study compared the yields of platelets and white blood cells across the three anticoagulant groups.
• Donor citrate reactions were monitored and compared between the anticoagulant formulations.

Main Results:

• ACD formula B demonstrated significantly higher yields of platelets and white blood cells compared to ACD formula A and 2% citrate.
• Both ACD formula B and 2% citrate resulted in a lower incidence of citrate reactions in donors.
• ACD formula A was associated with a higher rate of citrate reactions.

Conclusions:

• ACD formula B is a superior anticoagulant for plateletpheresis, enhancing yields of key blood components.
• ACD formula B and 2% citrate offer improved donor safety by reducing citrate reactions.
• The choice of anticoagulant significantly influences both the efficiency and safety of platelet collection.